• 1
    Lipatov AS, Govorkova EA, Webby RJ et al. Influenza: emergence and control. J Virol 2004; 78:89518959.
  • 2
    Tamura S, Tanimoto T, Kurata T. Mechanism of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005; 58:195207.
  • 3
    Gerhard W, Mozdzanowska K, Zharikova D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 2006; 12:569573.
  • 4
    Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerg Infect Dis 2006; 12:6672.
  • 5
    Palese P, García-Sastre A. Influenza vaccines: present and future. J Clin Invest 2002; 110:913.
  • 6
    Ben-Yedidia T, Arnon R. Epitope-based vaccine against influenza. Expert Rev Vaccines 2007; 6:939948.
  • 7
    Treanor JJ, Thierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza virus replication in mice. J Virol 1990; 64:13751377.
  • 8
    Frace AM, Klimov AI, Rowe T, Black RA, Katz JM. Modified M2 proteins produce heterosubtypic immunity to influenza A virus. Vaccine 1999; 17:22372244.
  • 9
    Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5:11191120.
  • 10
    Mozdzanowska K, Feng J, Eid M et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003; 21:26162626.
  • 11
    Gocník M, Fislová T, Mucha V et al. Antibodies induced by HA2 glycopolypeptide of influenza virus hemagglutinin improve recovery from influenza A virus infection. J Gen Virol 2008; 89:958967.
  • 12
    Eckert DM, Kay MS. Stalking influenza. Proc Natl Acad Sci USA 2010; 107:1356313564.
  • 13
    Bommakanti G, Citron MP, Hepler RW et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 2010; 107:1370113706.
  • 14
    Steel J, Lowen AC, Wang TT et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. Mbio 2010; 1:e0001810.
  • 15
    Wang TT, Tan GS, Hai R et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 2010; 107:1897918984.
  • 16
    Staneková Z, Király J, Stropkovská A et al. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Acta Virol 2011; 55:6167.
  • 17
    Smirnov YA, Lipatov SA, Gitelman AK, Claas ECJ, Osterhaus ADME. Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem. Arch Virol 2000; 145:17331741.
  • 18
    Prabhu N, Prabakaran M, Ho H-T et al. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol 2009; 83:25532562.
  • 19
    Sui J, Hwang WC, Perez S et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265273.
  • 20
    Wang TT, Tan GS, Hai R et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. Plos Pathog 2010; 6:e1000796.
  • 21
    Gerhard W. The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 2001; 260:171190.
  • 22
    Kostolanský F, Mucha V, Slováková R, Varečková E. Natural influenza A virus infection of mice elicits strong antibody response to HA2 glycopolypeptide. Acta Virol 2002; 46:229236.
  • 23
    Fislová T, Sládková T, Gocník M, Mucha V, Varečková E, Kostolanský F. Differences in antibody responses of mice to intranasal or intraperitoneal immunization with influenza A virus and vaccination with subunit influenza vaccine. Acta Virol 2005; 49:243250.
  • 24
    Styk B, Russ G, Poláková K. Antigenic glycopolypeptides HA1 and HA2 of influenza virus hemagglutinin. III. Reactivity with human convalescent sera. Acta Virol 1979; 23:18.
  • 25
    Graves PN, Schulman JL, Young JF, Palese P. Preparation of influenza virus subviral particles lacking the HA1 subunit of haemagglutinin: unmasking of crossreactive HA2 determinants. Virology 1983; 126:106116.
  • 26
    Becht H, Huang RTC, Fleischer B, Boschek CB, Rott R. Immunogenic properties of the small chain HA2 of the haemagglutinin of influenza viruses. J Gen Virol 1984; 65:173183.
  • 27
    Russ G, Poláková K, Kostolanský F, Styk B, Vančíková M. Monoclonal antibodies to glycopeptides HA1 and HA2 of influenza virus hemagglutinin. Acta Virol 1987; 31:374386.
  • 28
    Sánchez-Fauquier A, Villanueva N, Melero JA. Isolation of cross-reactive, subtype-specific monoclonal antibodies against influenza virus HA1 and HA2 hemagglutinin subunits. Arch Virol 1987; 97:251265.
  • 29
    Varečková E, Cox N, Klimov A. Evaluation of the subtype specificity of monoclonal antibodies raised against H1 and H3 subtypes of human influenza A virus hemagglutinins. J Clin Microbiol 2002; 40:22202223.
  • 30
    Varečková E, Mucha V, Kostolanský F, Gubareva LV, Klimov A. HA2-specific monoclonal antibodies as tools for differential recognition of influenza A virus antigenic subtypes. Virus Res 2008; 132:181186.
  • 31
    Throsby M, Van den Brink E, Jongeneelen M et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 recovered from human IgM+ memory B cells. PLoS ONE 2008; 12:E3942.
  • 32
    Nobusawa E, Aoyama T, Kato H, Suzuki Y, Tateno Y, Nakajima K. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 1991; 182:475485.
  • 33
    Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010; 16:13891391.
  • 34
    Varečková E, Mucha V, Wharton SA, Kostolanský F. Inhibition of fusion activity of influenza A haemagglutinin mediated by HA2-specific monoclonal antibodies. Arch Virol 2003; 148:469486.
  • 35
    Varečková E, Wharton SA, Mucha V, Gocník M, Kostolanský F. A monoclonal antibody specific to the HA2 glycoprotein of influenza A virus hemagglutinin that inhibits its fusion activity reduces replication of the virus. Acta Virol 2003; 47:229236.
  • 36
    Gocník M, Fislová T, Sládková T, Mucha V, Kostolanský F, Varečková E. Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection. J Gen Virol 2007; 88:951955.
  • 37
    Okuno Y, Matsumoto K, Isegava Y, Ueda S. Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 1994; 68:517520.
  • 38
    Lipatov AS, Gitelman AK, Smirnov YA. Prevention and treatment of lethal influenza A virus bronchopneumonia in mice by monoclonal antibody against hemagglutinin stem region. Acta Virol 1997; 41:337340.
  • 39
    Vanlandschoot P, Beirnaert ER, Barrere B et al. An antibody which binds to the membrane-proximal end of influenza virus haemagglutinin (H3 subtype) inhibits the low-pH-induced conformational change and cell-cell fusion but does not neutralize virus. J Gen Virol 1998; 79:17811791.
  • 40
    Lim APC, Chan CEZ, Wong SKK, Chan AHY, Ooi EE, Hnason BJ. Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library. Virol J 2008; 5:110.
  • 41
    Chen J, Wharton SA, Weissenhorn W et al. A soluble domain of the membrane-anchoring chain of the influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation. Proc Natl Acad Sci USA 1995; 92:1220512209.
  • 42
    WHO Manual on Animal Influenza Diagnosis and Surveillance. WHO/CDS/CSR/2002.5.
  • 43
    Stropkovská A, Mucha V, Fislová T, Gocník M, Kostolanský F, Varečková E. Broadly cross-reactive monoclonal antibodies against HA2 glycopolypeptide of influenza A haemagglutinin of H3 subtype reduce replication of influenza A viruses of human and avian origin. Acta Virol 2009; 53:1520.
  • 44
    Staneková Z, Varečková E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010; 7:351.